Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program (Hep C Treatment)

Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program
[Press Release] PR Newswire via Yahoo! Finance - Dec 21 5:03 AM
Sirna Therapeutics, Inc. , a leading RNAi therapeutics company, announced today that it has selected Sirna-AV34, a systemically delivered, chemically modified short interfering RNA compound, as its candidate for advancement to human clinical testing against Hepatitis C virus.Save to My Web

InterMune Completes Divestiture of Infergen(R) for Up to $135.5 Million in Cash
RedNova - Jan 03 7:33 AM
BRISBANE, Calif., Jan. 3 /PRNewswire-FirstCall/ -- InterMune, Inc.Save to My Web

Vertex drug shows promise in hepatitis C
Pharmaceutical Business Review - Jan 10 5:54 PM
New data from a phase Ib study show that Vertex Pharmaceuticals VX-950 dosed in combination with pegylated interferon alfa-2a, achieved a rapid and dramatic reduction in virus levels in genotype 1 patients with chronic hepatitis C infection.Save to My Web

New Vaccine Candidate Against Hepatitis C - University Of Saskatchewan's Vaccine And Infectious Disease Organization
Medical News Today - Jan 11 4:10 PM
Researchers at the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine candidate for hepatitis C, leading to hope in the fight against a disease for which no vaccines are yet available.Save to My Web

YOU ARE HERE:
Aidsmap - Jan 17 5:13 AM
HIV-positive patients who are coinfected with hepatitis C virus appear to have a less favourable immunological response to potent antiretroviral therapy than individuals who are only infected with HIV, according to a Canadian study published in the January 15 th edition of the Journal of Infectious Diseases . The researchers, from British Columbia, found that coinfected individuals had Save to My Web